Core Viewpoint - ACELYRIN, Inc. expresses confidence that the proposed merger with Alumis Inc. is the best path forward and maximizes value for stockholders [2][3] Company Overview - ACELYRIN is a late-stage clinical biopharma company focused on developing transformative medicines in immunology [2] - The merger with Alumis is seen as a strategic move to create a leading clinical-stage immunology company with a diversified portfolio [8] Merger Details - The ACELYRIN Board recommends stockholders vote "FOR" the merger, emphasizing the importance of every vote [5] - The merger agreement reflects a significant increase in ACELYRIN stockholders' ownership in the combined company, retaining approximately 48% ownership [8] - The merger follows a comprehensive review process by an independent transaction committee [8] Stockholder Engagement - The Board urges stockholders to protect their investment value and not be swayed by short-term focused investors [4] - A Special Meeting of stockholders is scheduled for May 13, 2025, to vote on the merger [1][5] Rights Plan - ACELYRIN adopted a limited duration rights plan in response to a rapid accumulation of its stock by Tang Capital, aiming to maximize stockholder value [6]